The US Food and Drug Administration (FDA) revealed today its intent to study Blockchain Healthcare Applications.
The American agency who approves and regulates medical products announced its decision in a press release published by IBM Watson Health, that will team together with the FDA.
IBM will study how data from electronic medical records, clinical trials and health data from devices can be better shared and audited by using the distributed ledger.
To do so, it is not clear if IBM and the FDA will use a private blockchain or the Bitcoin one. Details may be published during next months.
Initial tests will be focused on clinical trials and real-world evidence data related to oncological data.
However, the two companies positioned the trial as one that could one day mitigate the potential of patient privacy breaches during electric exchanges.
The official press release revealed:
“By keeping an audit trail of all transactions on an unalterable distributed ledger, blockchain technology establishes accountability and transparency in the data exchange process.”
According to the press release, the IBM and the FDA will work together for a two-years period and their goal is publishing their researches in 2017.
Open your free digital wallet here to store your cryptocurrencies in a safe place.